Eli Lilly on Wednesday said its experimental pill led to more weight loss and better control of blood sugar in patients with ...

Rybelsus becomes the first oral glucagon-like peptide-1 receptor agonist in the EU with proven cardiovascular benefits.

Novo Nordisk NVO has secured European approval to update the label of oral GLP-1 drug for type II diabetes (T2D), Rybelsus ...

Novo Nordisk's Rybelsus has become the first oral GLP-1 agonist to pick up a regulatory approval for cardiovascular risk ...

In a late-stage trial, an investigational GLP-1 pill from Eli Lilly helped diabetes patients lower their blood sugar and ...

Committee for Medicinal Products for Human Use (CHMP) approved an update to Novo Nordisk A/S‘ (NYSE:NVO) Rybelsus (oral ...

Novo Nordisk's Rybelsus gains EU approval for cardiovascular benefits, enhancing treatment options for type 2 diabetes and ...

Earlier this week, European regulators approved a label update for Novo Nordisk's Rybelsus to reflect cardiovascular benefits in people with Type 2 diabetes based on data from the SOUL clinical trial.

Bagsværd, Denmark, 15 September 2025 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the ...

Patients on Eli Lilly & Co.’s experimental diabetes pill lost more weight and had better blood sugar control than those on an ...

Ousted CDC director Susan Monarez says Kennedy planned to change pediatric vaccine schedule; Eli Lilly’s obesity pill beats Novo’s Rybelsus in latest study; Novo views semaglutide trial in Alzheimer’s ...

Rybelsus works best on an empty stomach. Taking it with food can reduce absorption, making it less effective. Taking the drug without food will help with better blood sugar management. Consider taking ...